We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Journal Articles

in Targeted and Immune Therapy

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Dermatology
Observation  | 
Complete Remission of Squamous Cell Carcinoma After Treatment With Panitumumab in a Patient With Cetuximab-Induced Anaphylaxis
Aurélie Marti, MS; Antoine Fauconneau, MD; Nora Ouhabrache, MD; et al.
JAMA Dermatology
Viewpoint  | 
Innovative New Drugs for Serious Nonlethal Diseases The Cost to Develop and the Cost to Buy
William H. Eaglstein, MD
JAMA Ophthalmology
Original Investigation  | 
Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
John A. Wells, MD; Adam R. Glassman, MS; Lee M. Jampol, MD; et al.
JAMA Oncology
From The JAMA Network  | 
Surrogates for Survival or Other End Points in Oncology
Michael LeBlanc, PhD; Catherine Tangen, DrPH